Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2011-07-05
2011-07-05
Allen, Marianne P (Department: 1647)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387900
Reexamination Certificate
active
07973140
ABSTRACT:
Antibodies directed to the antigen Ang-2 and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the antigen Ang-2. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies.
REFERENCES:
patent: 5521073 (1996-05-01), Davis et al.
patent: 5643755 (1997-07-01), Davis et al.
patent: 5650490 (1997-07-01), Davis et al.
patent: 5814464 (1998-09-01), Davis et al.
patent: 5851797 (1998-12-01), Valenzuela et al.
patent: 6166185 (2000-12-01), Davis et al.
patent: 6312694 (2001-11-01), Thorpe et al.
patent: 6342219 (2002-01-01), Thorpe et al.
patent: 6342221 (2002-01-01), Thorpe et al.
patent: 6455035 (2002-09-01), Suri et al.
patent: 7067475 (2006-06-01), Cerretti et al.
patent: 7205275 (2007-04-01), Oliner et al.
patent: 7485297 (2009-02-01), Wood et al.
patent: 7521053 (2009-04-01), Oliner
patent: 7658924 (2010-02-01), Oliner et al.
patent: 2003/0124129 (2003-07-01), Oliner
patent: 2006/0057138 (2006-03-01), Wood et al.
patent: 0784683 (2001-02-01), None
patent: 1130094 (2001-09-01), None
patent: 1165115 (2003-05-01), None
patent: 0821728 (2004-08-01), None
patent: WO 96/11269 (1996-04-01), None
patent: WO 96/31598 (1996-10-01), None
patent: WO 98/05779 (1998-02-01), None
patent: WO 00/02584 (2000-01-01), None
patent: WO 00/02587 (2000-01-01), None
patent: WO 00/64946 (2000-11-01), None
patent: WO 00/75323 (2000-12-01), None
patent: WO 01/14550 (2001-03-01), None
patent: WO 01/73027 (2001-10-01), None
patent: WO 01/75067 (2001-10-01), None
patent: WO 03/030833 (2003-04-01), None
Cai, Mingqing et al., “Single chain Fv antibody against angiopoietin-2 inhibits VEGF-induced endothelial cell proliferation and migration n vitro,” Biochemical and Biophysical Research Communications, 309 (2003) pp. 946-951.
Fiedler, Ulrike et a., “Angiopoietin-1 and Angiopoietin-2 Share the Same Binding Domains in the Tie-2 Receptor Involving the First Ig-like Loop and the Epidermal Growth Factor-like Repeats,” Journal of Biological Chemistry, vol. 278, No. 3, Jan. 17, 2003, pp. 1721-1727.
Lin, Pengnian et al., “Inhibition of Tumor Angiogenesis Using a Soluble Receptor Establishes a Role for Tie2 in Pathologic Vascular Growth,” Journal of Clinical Investigation, vol. 100, No. 8, Oct. 1997, pp. 2072-2078.
Maisonpierre, Peter C. et al., “Angiopoietin-2, a Natural Antagonist for Tie2 That Disrupts in vivo Angiogenesis,” Science, vol. 277, Jul. 4, 1997, pp. 55-60.
Oliner, Jonathan, “Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2,” Cancer Cell, Nov. 2004, vol. 6, No. 5, pp. 507-516.
Robinson, Candy S. et al., “The Effects of Angiopoietin-2 and Neutralizing Anti-Tie-2 Antibody on Microvessel Growth, Branching, and Regression in the Ex Vivo Rat Aortic Ring Explant Model of Angiogenesis,” Proceedings of the American Association for Cancer Research Annual Meeting, vol. 42, Mar. 2001, p. 2.
Ahmad, Syed A. et al., 2001, “The Effects of Angiopoietin-1 and -2 on Tumor Growth and Angiogenesis in Human Colon Cancer”, Cancer Research, 61:1255-1259.
Ahmad, Syed A. et al., 2001, “Differential Expression of Angiopoietin-1 and Angiopoietin-2 in Colon Carcinoma”, Cancer, 92:1138-1143.
Asahara, Takayuki et al., 1998, “Tie2 Receptor Ligands, Angiopoietin-1 and Angiopoietin-2, Modulate VEGF-Induced Postnatal Neovascularization”, Circ. Res. 83:233-240.
Bunone, Giuseppe et al., 1999, “Expression of Angiogenesis Stimulators and Inhibitors in Human Thyroid Tumors and Correlation with Clinical Pathological Features”, American Journal of Pathology, 155(6):1967-1976.
Cai, Mingqing, et al., 2003, “Single chain Fv antibody against angiopoietin-2 inhibits VEGF-induced endothelial cell proliferation and migration in vitro”, Biochemical and Biophysical Research Communications, 309:946-951.
Chen, Yvonne et al., 1999, “Selection and Analysis of an Optimized Anti-VEGF Antibody: Crystal Structure of an Affinity-matured Fab in Complex with Antigen”, J. Mol. Biol., 293:865-8813.
Chen, L. et al., 2001, “Expression of angiopoietin-2 gene and its receptor Tie2 in hepatocellular carcinoma”, J. Tongji Med. Univ., 21(3):228-230, 235. English Abstract Only.
Davis, Samuel et al., 1996, “Isolation of Angiopoietin-1, a Ligand for the TIE2 Receptor, by Secretion-Trap Expression Cloning”, Cell, 87:1161-1169.
Dumont, Daniel J., et al., 1994, “Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo”, Genes & Development, 8:1897-1909.
Etoh, Tsuyoshi et al., 2001, “Angiopoietin-2 Is Related to Tumor Angiogenesis in Gastric Carcinoma: Possible in Vivo Regulation via Induction of Proteases”, Cancer Research, 61:2145-2153.
Flessner, Michael F. et al., 2005, “Resistance of Tumor Interstitial Pressure to the Penetration of Intraperitoneally Delivered Antibodies into Metastatic Ovarian Tumors”, Clin Cancer Res., 11(8):3117-3125.
Fiedler, Ulrike et al., 2003, “Angiopoietin-1 and Angiopoietin-2 Share the Same Binding Domains in the Tie-2 Receptor Involving the First Ig-like Loop and the Epidermal Growth Factor-like Repeats”, The Journal of Biological Chemistry 278(3):1721-1727.
Gale, Nicholas W. et al., 2002, “Angiopoietin-2 Is Required for Postnatal Angiogenesis and Lymphatic Patterning, and Only the Latter Role Is Rescued by Angiopoietin-1”, Developmental Cell, 3:411-423.
Gura, Trisha, 1997, “Systems for Identifying New Drugs Are Often Faulty”, Science, 278:1041-1042.
Hanahan, Douglas, 1997, “Signaling Vascular Morphogenesis and Maintenance”, Science, 277 (5322):48-50.
Holash, J. et al., 1999, Vessel Cooption, Regression, and Growth in Tumors Mediated by Angiopoietins and VEGF, Science, 284:1994-1998.
Holash, J. et al., 1999, “New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF”, Oncogene, 18:5356-5362.
Jain, Rakesh K. 1990, “Physiological Barriers to Delivery of Monoclonal Antibodies and Other Macromolecules in Tumors”, Cancer Research, 50:814s-819s.
Kim, Injune et al., 1999, “Molecular cloning and characterization of a novel angiopoietin family protein, angiopoietin-3”, FEBS Letters 443:353-356.
Kim, Injune et al., 1999, “Molecular Cloning, Expression, and Characterization of Angiopoietin-related Protein”, The Journal of Biological Chemistry, 274(37):26523-26528.
Kim, Injune et al., 2000, “Angiopoietin-2 at high concentration can enhance endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway”, Oncogene, 19:4549-4552.
Koga, Kazunari et al., 2001, “Expression of Angiopoietin-2 in Human Glioma Cells and Its Role for Angiogenesis”, Cancer Research 61:6248-6254.
Korff, Thomas et al., 2001, “Blood vessel maturation in a 3-dimensional spheroidal coculture model: direct contact with smooth muscle cells regulates endothelial cell quiescence and abrogates VEGF responsiveness”, The FASEB Journal, 15:447-457.
Kwak, Hee Jin et al., 1999, “Angiopoietin-1 is an apoptosis survival factor for endothelial cells”, FEBS Letters, 448:249-253.
Lee, Ji Hee et al., 2001, “Comparative study of angiostatic and anti-invasive gene expressions as prognostic factors in gastric cancer”, International Journal of Oncology, 18:355-361.
Lewis, Claire E. et al., 2007, “Tie2-Expressing Monocytes and Tumor Angiog
Blakey David Charles
Emery Stephen Charles
Green Larry L.
Keyt Bruce A.
Yang Xiao-Dong
Allen Marianne P
MedImmune Limited
LandOfFree
Antibodies directed to angiopoietin-2 and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibodies directed to angiopoietin-2 and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies directed to angiopoietin-2 and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2715874